---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-023798"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T06:10:43.031141+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioLife Solutions Q1 revenue up 30% YoY to $23.9M; net loss narrows to $0.4M

## Summary
- Cell Processing revenue of $21.6M (+33% YoY), driven by biopreservation media demand from commercial therapies.
- GAAP net loss from continuing ops of $0.4M vs. $3.2M loss in Q1 2024; adjusted EBITDA of $5.7M (24% of revenue).
- FY 2025 revenue guidance reaffirmed at $95.5M-$99.0M, representing 16%-20% growth over 2024.
- Completed acquisition of PanTHERA CryoSolutions on April 4, 2025, adding novel cryopreservation IRI technology.
- Cash and marketable securities of $107.6M at quarter end; balance sheet supports organic and inorganic growth.

## SEC filing metadata
- accession: 0001628280-25-023798
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000162828025023798/0001628280-25-023798-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000162828025023798/blfs-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-023798
- JSON: https://secwatch.observer/filing/0001628280-25-023798.json
- Plain text: https://secwatch.observer/filing/0001628280-25-023798.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.